Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations

References

• WHO Guidelines on Hepatitis B and C Testing. Geneva: World Health Organization; 2017 Feb.ISBN-13, 978-92-4-154998-1 Available from: https://www.ncbi.nlm.nih.gov/books/NBK442272/. Accessed June 25, 2019. 
   Google Scholar
• Polaris Observatory HCV, 2017. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–176. doi:10.1016/S2468-1253(16)30181-928404132
   PubMed Web of Science ®Google Scholar
• Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep. 2011;8(1):12–22. European Association for the Study of the Liver. doi:10.1007/s11904-010-0071-321221855
   PubMedGoogle Scholar
• EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461–511. doi:10.1016/j.jhep.2018.03.02629650333
   PubMed Web of Science ®Google Scholar
• American Association for the Study of Liver Disease, Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C virus. 2017 Available from: http://www.hcvguidelines.org Accessed June 17, 2019.
   Google Scholar
• Chan HL, Tsang OT, Hui YT, et al. Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. J Gastroenterol Hepatol. 2017;32(6):1230–1233. doi:10.1111/jgh.1366327869328
   PubMed Web of Science ®Google Scholar
• Werner CR, Schwarz JM, Egetemeyr DP, et al. Second-generation direct-acting-antiviral hepatitis C virus treatment: efficacy, safety, and predictors of SVR12. World J Gastroenterol. 2016;22(35):8050–8059. doi:10.3748/wjg.v22.i35.805027672299
   PubMed Web of Science ®Google Scholar
• Sciences G. EPCLUSA (Sofosbuvir and Velpatasvir) [Package Insert]. CA, Foster City; 2016 Available from: https://ec.europa.eu/health/documents/community-register/2016/20160706135323/anx_135323_it.pdf. Accessed June 25, 2019.
   Google Scholar
• Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016;36(Suppl 1):47–57. doi:10.1111/liv.2016.36.issue-S126725897
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014;146(5):1176–1192. doi:10.1053/j.gastro.2014.03.00324631495
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163(1):1–13. doi:10.7326/M15-078525909356
   PubMed Web of Science ®Google Scholar
• Benítez-Gutiérrez L, Barreiro P, Labarga P, et al. Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opin Pharmacother. 2016;17(9):1215–1223. doi:10.1080/14656566.2016.118215627149603
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015;62(Suppl 1):S87–S99. doi:10.1016/j.jhep.2014.09.03325920094
   PubMed Web of Science ®Google Scholar
• Kwo PY, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017;67(2):263–271. doi:10.1016/j.jhep.2017.03.03928412293
   PubMed Web of Science ®Google Scholar
• Puoti M, Foster GR, Wang S, et al. High SVR12 with 8-week and 12-week Glecaprevir/Pibrentasvir: integrated analysis of HCV genotype 1-6 patients without cirrhosis. J Hepatol. 2018;69(2):293–300. doi:10.1016/j.jhep.2018.03.00729551706
   PubMed Web of Science ®Google Scholar
• Pol S, Parlati L. Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in “special populations”. Liver Int. 2018;38(Suppl 1):28–33. doi:10.1111/liv.1362629427485
   PubMed Web of Science ®Google Scholar
• European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153–194. doi:10.1016/j.jhep.2016.09.00127667367
   PubMed Web of Science ®Google Scholar
• Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64(2):486–504. doi:10.1016/j.jhep.2015.09.01126409317
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151(1):70–86. doi:10.1053/j.gastro.2016.04.00327080301
   PubMed Web of Science ®Google Scholar
• AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C; 2018 Available from: https://www.hcvguidelines.org/. Accessed June 17, 2019.
   Google Scholar
• Komatsu TE, Boyd S, Sherwat A, et al. Regulatory analysis of effects of hepatitis C virus NS5A polymorphisms on efficacy of elbasvir and grazoprevir. Gastroenterology. 2017;152(3):586–597. doi:10.1053/j.gastro.2016.10.01727773808
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Mizokami M, Pianko S, et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol. 2017;66(5):910–918. doi:10.1016/j.jhep.2017.01.00728108232
   PubMed Web of Science ®Google Scholar
• Harrington PR, Komatsu TE, Deming DJ, Donaldson EF, O’Rear JJ, Naeger LK. Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: regulatory analyses and perspectives. Hepatology. 2018;67(6):2430–2448. doi:10.1002/hep.2969329194682
   PubMed Web of Science ®Google Scholar
• Paolucci S, Premoli M, Novati S, et al. Baseline and breakthrough resistance mutations in HCV patients failing DAAs. Sci Rep. 2017;7(1):16017. doi:10.1038/s41598-017-15987-129167469
   PubMed Web of Science ®Google Scholar
• Lontok E, Harrington P, Howe A, et al. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology. 2015;62(5):1623–1632. doi:10.1002/hep.2793426095927
   PubMed Web of Science ®Google Scholar
• Sorbo MC, Cento V, Di Maio VC, et al. Hepatitis C virus drug resistance associated substitutions andtheir clinical relevance: update2018. Drug Resist Update. 2018;37:17–39. doi:10.1016/j.drup.2018.01.004
   PubMed Web of Science ®Google Scholar
• Sidharthan S, Kohli A, Sims Z, et al. Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. Clin Infect Dis. 2015;60(12):1743–1751. doi:10.1093/cid/civ17025733369
   PubMed Web of Science ®Google Scholar
• Ferenci P, Laferl H, Scherzer TM, et al. Austrian hepatitis study group. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008;135(2):451–458. doi:10.1053/j.gastro.2008.04.01518503773
   PubMed Web of Science ®Google Scholar
• Harrington PR, Zeng W, Naeger LK. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology. 2012;55(4):1048–1057. doi:10.1002/hep.2479122095516
   PubMed Web of Science ®Google Scholar
• Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384(9941):414–426. doi:10.1016/S0140-6736(14)60538-924907224
   PubMed Web of Science ®Google Scholar
• Ferenci P, Asselah T, Foster GR, et al. STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. J Hepatol. 2015;62(6):1246–1255. doi:10.1016/j.jhep.2014.12.02425559324
   PubMed Web of Science ®Google Scholar
• Tabernilla A, Grandal M, Pernas B, et al. Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration. Eur J Gastroenterol Hepatol. 2017;29(7):781–785. doi:10.1097/MEG.000000000000088228410351
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378(4):354–369. doi:10.1056/NEJMoa170241729365309
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Wedemeyer H, Cloherty G, et al. Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy. J Virol Methods. 2015;214:29–32. doi:10.1016/j.jviromet.2014.11.02725528998
   PubMed Web of Science ®Google Scholar
• Chatterjee A, Guedj J, Perelson AS. Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents? Antivir Ther. 2012;17(6Pt B):1171–1182. doi:10.3851/IMP242823186606
   PubMed Web of Science ®Google Scholar